POLYMED Q1 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹403 Cr
verified against source
Revenue YoY
5%
reported change
EBITDA
₹106 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Poly Medicure reported Q1 FY26 consolidated revenue of Rs 403 crore (5% YoY), with EBITDA at Rs 106 crore (26.3% margin) and PAT at Rs 93 crore (up 25.7% YoY). Domestic business outperformed with 20% growth to Rs 126 crore, driven by 25% private sector growth, partially offset by 10% government segment decline. International revenue declined 1% to Rs 275 crore, with Europe down 6.7% due to inventory destocking and Chinese dumping. The company signed two CDMO contracts (US and Hong Kong-based) for vascular access and pain management products, with revenues expected from FY27. New cardiology vertical deployed 1,350 stents with plans to reach 20,000 units by year-end. Management lowered international growth guidance to 5-10% (from 12-15%) citing geopolitical uncertainty but reiterated domestic 30% growth and EBITDA margin guidance of 25-27%. Capex guidance maintained at Rs 250+ crore for two new plants. Key risk: further tariff escalation could impact export recovery trajectory.
Colored figures show movement against the previous available record.
Guidance to track
- Company reiterated 30% domestic growth target, requiring significantly higher growth in remaining 9 months as Q1 domestic grew 20%. Cardiology and critical care divisions ramping up to drive acceleration.
- Lowered from earlier 12-15% guidance reflecting current geopolitical realities. Europe showed -6.7% in Q1; management expects double-digit growth in remaining 9 months to achieve 5-10% full-year target.
- Q1 EBITDA margin at 26.3%, within stated range. Management targets to beat this range as higher-margin new products (cardiology, critical care) scale up and revenue accelerates.
- Two new manufacturing facilities under construction in Palwal and Haridwar. Palwal plant includes gamma sterilization facility (Phase 1 operational) expanding capacity from 300 to 2,000 kCi.
Risks flagged
- Chinese companies aggressively dumped products in European market due to US-China tariff situation, causing customer inventory reduction from 4-5 months to 2-3 months. While green shoots visible, full recovery uncertain.
- 50% tariff on India-US trade flagged as unsustainable. While current US revenue <$3.5 million (insulated), uncertainty around US market expansion and CDMO contracts (one US partner) creates execution risk.
- Analyst Batra pointedly asked about lessons from being 'caught by surprise' as international growth guidance was revised sharply downward within a year. Management acknowledged signs were visible last quarter but recalibration happened only after Q1 impact.
- Government segment declined 10% in Q1 as company exits low-margin business, consistent with strategy but creates near-term revenue headwind until private sector ramp-up compensates.
Key quotes
- We are recalibrating for the US market. We said we'll not be overdependent on one market like Europe. And now we have opened a subsidiary in Brazil for our direct presence.
- The signs were there in the last quarter already. See brother always you have to recalibrate. So our recalibration was focus more on India. That was our first recalibration.
- We are on track and I think even in the coming quarters you will see the improvement. I'm very sure and definitely we will commit only what we can do. We will not commit something higher and say we didn't do it.
Research modules